Literature DB >> 11053249

Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy.

A Venuti1, D Salani, V Manni, F Poggiali, A Bagnato.   

Abstract

Human papillomaviruses (HPV) are associated with cervical cancer and interact with growth factors that may enhance malignant transformation of cervical carcinoma cells. Endothelin-1 (ET-1) is released from HPV transfected keratinocytes and induces increased growth response in these cell lines in comparison with normal cells. In the present study several cervical carcinoma cell lines have been analyzed to investigate the expression of ET-1 and its receptors as well as their involvement in tumor growth. All HPV-positive cancer cells secreted ET-1 and expressed mRNA for ET-1 and its receptors, whereas a HPV-negative carcinoma cell line expressed only the ETBR mRNA and didn't secrete ET-1. Binding studies showed that HPV-associated cells expressed an increased number of functional ETAR. ET-1 stimulated a marked dose-dependent increase in [3H]-thymidine incorporation with respect to the normal cells whereas ET-3 and ETBR agonists had no effect. In HPV-positive cancer cells, a specific antagonist of ETAR inhibited the proliferation induced by ET-1 and substantially reduced the basal growth rate of unstimulated cervical tumor cells, whereas the ETBR antagonist had no effect. These results demonstrate that ET-1 participates in the progression of neoplastic growth in HPV-associated carcinoma, in which ETAR are increased and could be targeted for antitumor therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053249     DOI: 10.1096/fj.00-0024com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

Review 1.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

2.  Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells.

Authors:  A Bagnato; L Rosanò; V Di Castro; A Albini; D Salani; M Varmi; M R Nicotra; P G Natali
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

Review 4.  Endothelin 1 in cancer: biological implications and therapeutic opportunities.

Authors:  Laura Rosanò; Francesca Spinella; Anna Bagnato
Journal:  Nat Rev Cancer       Date:  2013-07-25       Impact factor: 60.716

5.  Endothelin receptor A blockade enhances taxane effects in prostate cancer.

Authors:  Ardavan Akhavan; Kevin H McHugh; Georgi Guruli; Robert R Bies; William C Zamboni; Sandra A Strychor; Joel B Nelson; Beth R Pflug
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

6.  Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Emily Brantley; Seok Joong Yun; Junqin He; Marva Maya; Fahao Zhang; Qiuyu Wu; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

7.  Effect of endothelin-1 in esophageal squamous cell carcinoma invasion and its correlation with cathepsin B.

Authors:  Wen-Jie Jiao; Jing Xu; Hao Pan; Tian-You Wang; Yi Shen
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

Review 8.  From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors.

Authors:  Oana Draghiciu; Hans W Nijman; Toos Daemen
Journal:  Clin Dev Immunol       Date:  2011-12-08

9.  Elevation of circulating big endothelin-1: an independent prognostic factor for tumor recurrence and survival in patients with esophageal squamous cell carcinoma.

Authors:  Wenjie Jiao; Jing Xu; Jinsheng Zheng; Yi Shen; Lesheng Lin; Jian Li
Journal:  BMC Cancer       Date:  2008-11-15       Impact factor: 4.430

10.  Endothelin receptors as novel targets in tumor therapy.

Authors:  Anna Bagnato; Pier Giorgio Natali
Journal:  J Transl Med       Date:  2004-05-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.